SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

UroGen Pharma Says First Patient Dosed in UGN-501 Phase 1 Trial

Valid market news retained in the public archive without immediate LiveCast distribution.

URGN

Related stories